📷 Image: Wikimedia Commons / PMO Barbados from Bridgetown, Barbados
Health
US FDA Grants Approval to AstraZeneca's Breast Cancer Pill Etcamah
✍️ Livemint
🗓 05 Sep 2026, 01:17 PM
👁 3
The US Food and Drug Administration has approved Etcamah, a new oral therapy from AstraZeneca for treating breast cancer, outlining its dosage and safety profile.
Washington – The US Food and Drug Administration (FDA) has formally approved Etcamah, an oral medication developed by AstraZeneca for the treatment of breast cancer. The approval follows a review of clinical data that demonstrated the drug's efficacy in patients with advanced disease.
The FDA label specifies the recommended dosage regimen and highlights that the drug carries a higher risk profile for certain patient groups. Physicians are advised to assess individual risk factors before prescribing Etcamah.
AstraZeneca has released detailed information on potential side effects, urging healthcare providers to monitor patients closely during therapy. The company expects the drug to become available in the US market later this year.
The approval marks a significant addition to the therapeutic options for breast cancer, a disease that affects millions worldwide. Experts note that oral agents like Etcamah can improve convenience compared to intravenous treatments.
Regulatory approval also opens pathways for further studies to explore Etcamah's use in combination with other cancer therapies.
The FDA label specifies the recommended dosage regimen and highlights that the drug carries a higher risk profile for certain patient groups. Physicians are advised to assess individual risk factors before prescribing Etcamah.
AstraZeneca has released detailed information on potential side effects, urging healthcare providers to monitor patients closely during therapy. The company expects the drug to become available in the US market later this year.
The approval marks a significant addition to the therapeutic options for breast cancer, a disease that affects millions worldwide. Experts note that oral agents like Etcamah can improve convenience compared to intravenous treatments.
Regulatory approval also opens pathways for further studies to explore Etcamah's use in combination with other cancer therapies.